Key result
Dapagliflozin attenuates skeletal muscle atrophy and normalizes pH in preclinical heart failure.
Why the study?
Does dapagliflozin mitigate skeletal muscle pathology in an animal model of heart failure?
Does dapagliflozin mitigate skeletal muscle pathology in an animal model of heart failure?
Dapagliflozin mitigates skeletal muscle pathology and normalizes plasma pH in a rat model of heart failure, suggesting a potential mechanism for its benefits in HF-related muscle dysfunction.
-ATPase, Nav1.4) in HS vs LS animals. Furthermore, HS rats showed an increased CaMKII expression in its active phosphorylated form and a change in plasma pH toward acidification. Dapagliflozin treatment counteracted the altered expression of most of the components under investigation, also promoting an amelioration of atrophy indexes and a recovery of plasma pH. Thus, skeletal muscle appears highly responsive to SGLT2i treatment, supporting the potential of these drugs in mitigating HF-related muscle pathology.
No takes yet. Share an insight, caveat, or question.
Conte et al. (2025) studied Heart failure (animal model). Dapagliflozin vs. Control/untreated animals was evaluated on Skeletal muscle pathology (protein expression, atrophy indexes, plasma pH). Dapagliflozin treatment in a rat model of heart failure counteracted altered protein expression, ameliorated atrophy indexes, and recovered plasma pH in skeletal muscle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: